Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
12/2000
12/28/2000CA2377246A1 Arylthiazolidinedione and aryloxazolidinedione derivatives
12/28/2000CA2376733A1 Aromatic and heterocyclic derivatives of phytosterols and/or phytostanols for use in treating or preventing cardiovascular disease
12/28/2000CA2376081A1 Cysteinyl protease inhibitors
12/28/2000CA2375781A1 Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abci
12/28/2000CA2375771A1 Nucleic and proteinic acids corresponding to human gen abc1
12/28/2000CA2375508A1 Methods and products for manipulating uncoupling protein expression
12/28/2000CA2375493A1 Human transport proteins
12/28/2000CA2375484A1 In vivo insect model system for type-2 diabetes
12/28/2000CA2375407A1 Rna metabolism proteins
12/28/2000CA2375396A1 High molecular weight primary aliphatic alcohols obtained from beeswax and pharmaceutical use thereof
12/28/2000CA2375207A1 Peptide having preptin functionality
12/28/2000CA2340319A1 Method for producing plants with increased flavonoid and phenolic compound content
12/27/2000EP1063292A2 DNA encoding human alpha 1 adrenergic receptors and uses thereof
12/27/2000EP1063291A2 DNA encoding human alpha 1 adrenergic receptors and uses thereof
12/27/2000EP1062954A1 Process for producing glycolytic metabolism regulators
12/27/2000EP1062323A2 Methods of diagnosis and triage using cell activation measures
12/27/2000EP1062264A2 Enzyme inhibitors
12/27/2000EP1062246A1 Anti-inositolphosphoglycan monoclonal antibodies
12/27/2000EP1062240A1 N-terminally modified glp-1 derivatives
12/27/2000EP1062229A1 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
12/27/2000EP1062222A1 Serine peptidase modulators
12/27/2000EP1062218A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
12/27/2000EP1062216A1 Inhibitors of phospholipase a2
12/27/2000EP1062210A1 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
12/27/2000EP1062204A1 Modulators of protein tyrosine phosphatases (ptpases)
12/27/2000EP1062199A1 Modulators of protein tyrosine phosphatases (ptpases)
12/27/2000EP1061947A1 Stabilized aqueous peptide solutions
12/27/2000EP1061946A1 Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
12/27/2000EP1061927A1 Composition for reducing serum cholesterol levels
12/27/2000EP1061887A1 Novel use of phospholipids of vegetable and animal origin in nutritional therapy
12/27/2000EP1061812A1 Food products having enhanced cocoa polyphenol content and processes for producing same
12/27/2000CN1278263A 2,3-diaryl-pyrazolo [1,5-B] pyridazines derivatives, their prepn. and use as cyclooxygenase 2 (cox-2) inhibitors
12/27/2000CN1278182A Citrus peel extract as inhibitor of acyl CoA-cholesterol-0-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall
12/27/2000CN1278181A Method for treating diabetes, hyperglycemia and hypoglycemia
12/27/2000CN1278180A Method for treating hypercholesterolemia by using unsubstituted polydiallylamine
12/27/2000CN1278175A Compositions of lipid lowering agents
12/27/2000CN1278171A Naringin and naringenin as inhibitor of acyl coa-cholesterol-o-acyltransferase, ihibitor of macrophage-lipid complex accumulation on the arterial wall and preventive agent
12/27/2000CN1278170A Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive agent
12/27/2000CN1277965A Luogelie ketone hydrochloride and its use
12/27/2000CN1277962A Novel substituted dipolymer compounds, prepn. method therefor, pharmaceutical compositions contg. same
12/27/2000CN1277872A Process for extracting linoleic acid and producing soft capsule contg. linoleic acid
12/27/2000CN1277856A Help producing saliva and slaking thirst traditional Chinse medicine powder
12/27/2000CN1277850A Pharmaceutical for treating diabetes, and its prepn. process
12/27/2000CN1277847A Isomaltooligose oral liquor for treating diabetes and hypertension, and method for preparing same
12/27/2000CN1059902C Estrogen excitant/antagonist
12/26/2000US6166221 Intermediate for 4-(hydroxy-5-(1-imidazolyl)-2-methylbenzyl)-3,5-dimethylbenzoic acid useful as a thromboxane synthetase inhibitor and an agent for the prophylaxis and treatment of diabetes
12/26/2000US6166219 Treatment of diabetes and related disorders
12/26/2000US6166206 Pyrrolo[3,4-D]Pyrimidinone derivatives and their use as medicaments
12/26/2000US6166193 Nucleotide sequence which encodes g-protein coupled receptor; for the treatment and prevention of bacterial, fungal, protozoan and viral infections; for use in gene therapy
12/26/2000US6166192 PGC-1, a novel brown fat PPARγ coactivator
12/26/2000US6166080 Aminoquanidine carboxylates for the treatment of obesity
12/26/2000US6166077 Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1
12/26/2000US6166070 Kodaistatins A, B, C and D, a process for their production and their use
12/26/2000US6166063 Antidiabetic agents; antiarthritic agents; osteoporosis
12/26/2000US6166049 A treatment and/or prophylaxis of hyperglycaemia, pre-diabetic insulin resistance syndrome by administering an agonist of peroxisome proliferator-activated receptor to stimulate fatty oxidation
12/26/2000US6166048 Pharmaceutical compositions for inhibition of cytokine production and secretion
12/26/2000US6166043 Insulin sensitivity enhancer such as pioglitazone in combination with a biguanide such as metformin
12/26/2000US6166042 Pharmaceutical composition
12/26/2000US6166040 Treating a disorder of the central nervous system
12/26/2000US6166025 A stable, aqueous drug formulation for treating migraine
12/26/2000US6166017 Method of using ketoconazole and related substances in medicaments for treatment of type II diabetes and methods of treating same
12/26/2000US6165996 Compounds with chelation affinity selectivity for first transition series elements: use in medical therapy and diagnosis
12/26/2000US6165984 Administering an effective amount of naringin or naringenin to the human to prevent acylcoa-cholesterol-o-acyltransferase activity to treat hepatic diseases; inhibiting accumulation of macrophage-lipid complex on the arterial endothelium
12/26/2000US6165974 Administering an effective dose of a pharmaceutical preparation comprising at least two coagulation factors which are components of a prothrombinase or of a pro-prothrombinase to the patient for the treatment of acute bleeding
12/26/2000US6165790 Antisense modulation of PI3 kinase p55 gamma expression
12/26/2000US6165771 Compounds
12/26/2000US6165738 Hybrid of two human isoforms; for recombinant production; for diagnosis, presymptomatic detection, and prevention of insulin dependent diabetes mellitus
12/21/2000WO2000077255A1 49 human secreted proteins
12/21/2000WO2000077233A2 Complement-resistant non-mammalian dna viruses and uses thereof
12/21/2000WO2000077225A1 A novel insulin signaling molecule
12/21/2000WO2000077211A1 Pyrexia-associated genes and pyrexia-associated proteins of plant
12/21/2000WO2000077186A2 Bacterial protection against stress
12/21/2000WO2000077179A2 Human poly(adp-ribose) polymerase 2 materials and methods
12/21/2000WO2000077022A1 50 human secreted proteins
12/21/2000WO2000077021A1 48 human secreted proteins
12/21/2000WO2000077018A2 Purine derivatives
12/21/2000WO2000077011A1 Organosilyl compounds having nuclear hormone receptor modulating activity
12/21/2000WO2000077010A2 Substituted heterocycle fused gamma-carbolines
12/21/2000WO2000077002A1 Substituted heterocycle fused gamma-carbolines
12/21/2000WO2000077001A1 Substituted heterocycle fused gamma-carbolines
12/21/2000WO2000076995A1 Process for the preparation of (-)-1,4-benzothiazine-2-acetic acid derivatives
12/21/2000WO2000076988A1 Rhodanine derivatives and their use in inhibiting and imaging amyloids
12/21/2000WO2000076984A2 Novel compounds, their use and preparation
12/21/2000WO2000076523A1 Methods for modulating fxr receptor activity
12/21/2000WO2000076503A1 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2
12/21/2000WO2000076482A1 Novel formulations comprising lipid-regulating agents
12/21/2000WO2000076478A1 Controlled release and taste masking oral pharmaceutical compositions
12/21/2000WO2000066736B1 Growth factor homolog zvegf4
12/21/2000WO2000051987A3 Inhibitors of advanced, post-amadori glycosylation reactions
12/21/2000WO2000047580A3 Phenyl urea and phenyl thiourea derivatives
12/21/2000WO2000046240A3 Polypeptides involved in immune response
12/21/2000WO2000045791A3 Method for controlling liposome size
12/21/2000WO2000044709A3 ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS
12/21/2000WO2000044391A3 Plasminogen kringle 4 region fragments and methods of use
12/21/2000WO2000038660A3 Use of bisphosphonates for the prevention and treatment of infectious processes
12/21/2000DE19927574A1 Increasing content of flavonoids and phenols in plants, useful for e.g. preventing cardiovascular disease, by reducing activity of flavanone-3-hydroxylase
12/21/2000DE19927571A1 Increasing the levels of flavonoids and phenolic compounds in plants comprises treating the plants with growth-regulating 4-acyl-3,5-dioxo-1-cyclohexanecarboxylic acid derivatives
12/21/2000CA2686633A1 Combination therapy for effecting weight loss and treating obesity
12/21/2000CA2387696A1 48 human secreted proteins
12/21/2000CA2383048A1 49 human secreted proteins
1 ... 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 ... 1298